Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-122 vs Concomitant Therapy in Uncontrolled Glaucoma
NCT03193333Phase 3Terminated
- Sponsor
- Laboratorios Sophia
- Start
- Nov 2017
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of dorzolamide + timolol + brimonidine in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Laboratorios Sophia. Started Nov 2017; status: terminated.
02
Drugs
dorzolamide + timolol + brimonidine
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03193333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193333.